[go: up one dir, main page]

AR023939A1 - COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT - Google Patents

COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT

Info

Publication number
AR023939A1
AR023939A1 ARP000102095A ARP000102095A AR023939A1 AR 023939 A1 AR023939 A1 AR 023939A1 AR P000102095 A ARP000102095 A AR P000102095A AR P000102095 A ARP000102095 A AR P000102095A AR 023939 A1 AR023939 A1 AR 023939A1
Authority
AR
Argentina
Prior art keywords
preparation
pharmaceutical compositions
combination
useful
ccr5
Prior art date
Application number
ARP000102095A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR023939A1 publication Critical patent/AR023939A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto representado por la formula estructural 2 o de una sal farmacéuticamente aceptable de los mismos, donde R, R1, R2, R14, R15,R16 y X tienen elsignificado dado en la memoria descriptiva, también composiciones farmacéuticas y equipos quelo s comprenden, y el uso de los mismos para la preparacion demedicamentos para el tratamiento de HIV, rechazo a los transplantes de organos solidos, enfermedad de injerto versus huésped, artritis, artritis reumatoide,enfermedad inflamatoria delintesti no, dermatitis atopica, psoriasis, asma, alergias o esclerosis multiple, así como en combinacion de antagonistas CCR5 conagentes antivirales que son utiles en el tratamiento de HIV o agentes que son utiles en el tratamiento de enfermedadesinflamator ias.
ARP000102095A 1999-05-04 2000-05-02 COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT AR023939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30518799A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
AR023939A1 true AR023939A1 (es) 2002-09-04

Family

ID=23179704

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102095A AR023939A1 (es) 1999-05-04 2000-05-02 COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT

Country Status (32)

Country Link
EP (2) EP1175402B1 (es)
JP (3) JP3894729B2 (es)
KR (1) KR100439357B1 (es)
CN (2) CN1524527A (es)
AR (1) AR023939A1 (es)
AT (1) ATE299866T1 (es)
AU (2) AU780983B2 (es)
BR (1) BR0010607A (es)
CA (1) CA2371587C (es)
CO (1) CO5170522A1 (es)
CZ (1) CZ301161B6 (es)
DE (1) DE60021371T2 (es)
DK (1) DK1175402T3 (es)
EG (1) EG24533A (es)
ES (1) ES2246233T3 (es)
HK (1) HK1039330B (es)
HU (1) HUP0203528A3 (es)
IL (1) IL145742A0 (es)
MY (1) MY141473A (es)
NO (1) NO322044B1 (es)
NZ (1) NZ514675A (es)
PE (1) PE20010113A1 (es)
PL (1) PL203117B1 (es)
PT (1) PT1175402E (es)
RU (2) RU2266281C2 (es)
SA (1) SA00210270B1 (es)
SI (1) SI1175402T1 (es)
SK (1) SK286968B6 (es)
TR (2) TR200402496T2 (es)
TW (1) TWI283666B (es)
WO (1) WO2000066559A1 (es)
ZA (1) ZA200108867B (es)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
DK1373256T3 (da) * 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
JP3857270B2 (ja) * 2001-07-02 2006-12-13 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
AR036882A1 (es) 2001-10-15 2004-10-13 Schering Corp Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales
US6818773B2 (en) 2001-10-15 2004-11-16 Schering Corporation Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
MXPA04005155A (es) * 2001-11-29 2004-08-11 Schering Corp Preparacion de sales farmaceuticas de 4((z) -(4-bromofenil) (etoxiimino)]-1`-((2, 4-dimetil-1 -oxido-3 -piridinil) carbonil]-4` -metil-1, 4`-bipiperidina como antagonistas del receptor ccr5 para el tratamiento de sida y de infecciones de vih relacion
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
JP4538237B2 (ja) * 2002-03-29 2010-09-08 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとしてのピペリジン化合物およびピペラジン化合物の合成
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
JP2004107298A (ja) * 2002-09-20 2004-04-08 Takeda Chem Ind Ltd ウレア化合物およびその用途
AU2003266528A1 (en) * 2002-09-20 2004-04-08 Takeda Pharmaceutical Company Limited Cyclic amine compound, process for producing the same, and use
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
RU2005118407A (ru) * 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
BRPI0411414A (pt) * 2003-06-13 2006-07-25 Schering Ag derivados de quinolil amida como antagonistas de cdr-5
WO2005007608A2 (en) 2003-07-10 2005-01-27 Schering Corporation Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
BRPI0507586A (pt) 2004-02-10 2007-07-03 Hoffmann La Roche moduladores de receptor de quimiocina ccr5
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
ES2431524T3 (es) 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
ES2297727T3 (es) 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
PE20090123A1 (es) 2004-09-13 2009-03-10 Ono Pharmaceutical Co Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006077499A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Chemical compounds
MX2007009945A (es) * 2005-02-16 2007-09-26 Schering Corp Piperazinas sustituidas con heterociclicos con actividad antagonista de cxcr3.
EP1858886A1 (en) 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
US20090124636A1 (en) * 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
DE602007013573D1 (de) 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
US20110059154A1 (en) * 2008-02-29 2011-03-10 Strizki Julie M Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
LT2593452T (lt) 2010-07-14 2017-04-10 Novartis Ag Heterocikliniai junginiai, kaip ip receptoriaus agonistai
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
JP6058698B2 (ja) 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CR20160277A (es) 2013-12-19 2016-10-14 Bayer Pharma AG Piperidinil tetrahidroquinolinas sustituidas
WO2015091415A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
CN106029657A (zh) 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
JP3068206B2 (ja) * 1996-07-10 2000-07-24 シェーリング コーポレイション ムスカリン様アンタゴニストとしての１，４―ジ―置換ピペリジン
WO1998004125A1 (en) * 1996-07-25 1998-02-05 Terence George Mackay Improvements in or relating to fishing
CZ43399A3 (cs) * 1996-08-15 1999-07-14 Schering Corporation Etheroví muskarinní antagonisté
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity

Also Published As

Publication number Publication date
NO20015365D0 (no) 2001-11-02
DE60021371D1 (de) 2005-08-25
KR20020019906A (ko) 2002-03-13
PE20010113A1 (es) 2001-02-05
AU4501000A (en) 2000-11-17
IL145742A0 (en) 2002-07-25
MY141473A (en) 2010-04-30
CN1524527A (zh) 2004-09-01
HUP0203528A2 (hu) 2003-02-28
RU2005120376A (ru) 2006-12-27
HUP0203528A3 (en) 2003-11-28
NZ514675A (en) 2004-05-28
DK1175402T3 (da) 2005-11-21
JP2011219493A (ja) 2011-11-04
TR200103213T2 (tr) 2002-03-21
PL351412A1 (en) 2003-04-22
SK286968B6 (sk) 2009-08-06
JP3894729B2 (ja) 2007-03-22
KR100439357B1 (ko) 2004-07-07
NO322044B1 (no) 2006-08-07
ES2246233T3 (es) 2006-02-16
EP1659111A2 (en) 2006-05-24
AU780983B2 (en) 2005-04-28
EP1175402A1 (en) 2002-01-30
TR200402496T2 (tr) 2005-01-24
BR0010607A (pt) 2002-02-13
TWI283666B (en) 2007-07-11
PT1175402E (pt) 2005-11-30
EP1659111A3 (en) 2007-05-09
JP2006225407A (ja) 2006-08-31
SI1175402T1 (en) 2005-10-31
CA2371587C (en) 2005-09-13
CO5170522A1 (es) 2002-06-27
CN1349504A (zh) 2002-05-15
ATE299866T1 (de) 2005-08-15
AU2005202358B2 (en) 2008-01-10
CA2371587A1 (en) 2000-11-09
JP2002543186A (ja) 2002-12-17
ZA200108867B (en) 2003-03-26
AU2005202358A1 (en) 2005-06-23
SA00210270B1 (ar) 2006-09-04
PL203117B1 (pl) 2009-08-31
RU2266281C2 (ru) 2005-12-20
CZ20013941A3 (cs) 2002-04-17
HK1039330B (zh) 2005-12-09
WO2000066559A1 (en) 2000-11-09
NO20015365L (no) 2002-01-03
DE60021371T2 (de) 2006-04-27
EG24533A (en) 2009-08-30
CZ301161B6 (cs) 2009-11-18
CN1151131C (zh) 2004-05-26
HK1039330A1 (en) 2002-04-19
SK15672001A3 (sk) 2002-06-04
EP1175402B1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
AR023939A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT
AR023823A1 (es) Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos.
BR0212108A (pt) Derivados de piperidina úteis como antagonistas de ccr5
PT1003504E (pt) Compostos quimicos
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
AR033367A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ATE386725T1 (de) Heterocyclylverbindungen
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
IS6658A (is) Ný efnasambönd
NO20023932D0 (no) Nye forbindelser
PA8548701A1 (es) Azaindoles
FI951454A (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
SE0302116D0 (sv) Novel compounds
BRPI0410219A (pt) composições farmacêuticas de vareniclina
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
MA26418A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant
CL2004001325A1 (es) Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas.
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
AR019871A1 (es) Una composicion farmaceutica que comprende inhibidores del factor de transcripcion nf-kb y el uso de los mismos para la manufactura de un medicamento
MY147899A (en) Piperidine derivatives useful as ccr5 antagonists
BRPI0407335A (pt) Agentes antibacterianos
WO2005042517A3 (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors

Legal Events

Date Code Title Description
FB Suspension of granting procedure